Government Fees and Ministerial Resolution 347-2023

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Nicaraguan device registration fees are not priced in NTON 24001:2023 itself. Chapter 5, Article 10 of the standard refers to the applicable legal norms, and in practice the schedule sits in Ministerial Resolution No. 347-2023. The official PDF examined for this review is a 24-page scan without a text layer, so the amounts cannot be verified line by line, and this article therefore lists no figures: amounts follow the official publication in force at the time. What can be verified is the set of five payment nodes and the receipt rule. Registration processing, renewal, first-marketing quality testing, the classification certificate and the CLV each carry their own payment item, all are evidenced by a ROC receipt, and the receipt remains valid for a maximum of six months from the date of payment.

  • The fee schedule is set by RM 347-2023, not by the technical standard (Chapter 5, Article 10).
  • Amounts must be taken from the official publication in force; the scanned PDF does not permit line-by-line verification.
  • Five payment nodes exist: registration, renewal, first-marketing testing, classification certificate and CLV.
  • A ROC receipt is the evidence of payment at every node (Chapter 6, item 1).
  • Every ROC receipt is valid for six months from payment (Chapter 6, item 1; Chapter 8, Article 1 b).
  • A cancellation voids the payment and requires a fresh one (RA 0007/2025, Anexo I, Article 12 item 3).

2. Legal basis

The fee structure is built in three layers: the technical standard authorises charging, the ministerial resolution prices the services, and individual provisions identify when payment is due. The table sets out each layer.

Technical standardNTON 24001:2023, Tecnología de la salud. Dispositivos médicos. Requisitos para el Registro Sanitario (La Gaceta No. 192, 21 October 2024)Chapter 5, Article 10The registration processing fee is determined by the applicable legal norms
Fee scheduleResolución Ministerial N° 347-2023, Lista actualizada de pago por servicios que presta el Instituto de Investigación en Salud (INIS), SILAIS y las instancias de la Autoridad Nacional de Regulación SanitariaWhole textSchedule of fees; amounts follow the official publication in force
Technical standardNTON 24001:2023Chapter 6, item 1The ROC payment receipt for a new registration, modification or post-registration change is valid for a maximum of six months from payment
Technical standardNTON 24001:2023Chapter 8, Article 1 bRenewal fee; the same six-month validity applies to the ROC receipt
Technical standardNTON 24001:2023Chapter 7, Article 8First-marketing quality testing is paid separately, at rates also set by RM 347-2023
Technical standardNTON 24001:2023Annex D, Article 2 a; Annex E, Article 2 aThe classification certificate and the CLV each have their own payment item

3. Expert insights

Insight one: the fee chain has three links. NTON Chapter 5, Article 10 authorises the charge; RM 347-2023 sets the price; the individual provisions identify the moment of payment. The standard dates from 2023 and the schedule can be updated independently, which explains why no amount appears anywhere in the body of the standard — it says only that payment must be made as required by law.

Insight two: the five payment nodes are separate items. Registration processing (Chapter 6, item 1), renewal (Chapter 8, Article 1 b), first-marketing quality testing (Chapter 7, Article 8), the classification certificate (Annex D, Article 2 a) and the CLV (Annex E, Article 2 a) are budgeted separately rather than folded into a single registration charge.

Insight three: the treatment of amounts here is deliberate omission, not estimate. Because the official PDF is a scan without a text layer, line-by-line verification cannot be completed, and quoting an unverified figure would breach the principle that every statement must be checkable. The gap is left open on purpose rather than filled with an approximation.

Insight four: the six-month validity is the only timing rule, and it applies uniformly. Chapter 6, item 1 and Chapter 8, Article 1 b are drafted in identical terms. Once the receipt expires there is no extension mechanism; payment has to be made again.

Insight five: a cancellation voids the payment already made. Article 12 item 3 of Anexo I to RA 0007/2025 states «deberá iniciar uno nuevo iniciando con el pago del arancel correspondiente» — a new procedure must be started, beginning with payment of the corresponding fee. Fee management and correction-deadline management are therefore the same task, and a missed correction deadline costs more than time.

Insight six: one concrete amount is verifiable in the current texts. Article 24 of Anexo I to RA 0001/2026 sets a fee of C$364.74 (Nicaraguan córdobas) where correction of a power is requested more than five working days after approval has been withdrawn. It is the only specific amount verified here, and it confirms that the schedule is denominated in córdobas.

4. Practical recommendations

  • Take amounts only from the RM 347-2023 publication in force; do not use historical figures or third-party restatements.
  • Budget by the five nodes — registration, renewal, first-marketing testing, classification certificate and CLV — rather than as one lump sum.
  • Log the payment date and set a six-month expiry reminder (Chapter 6, item 1; Chapter 8, Article 1 b).
  • Monitor ROC validity during any correction phase, since a cancellation means paying again.
  • Schedule payment after the dossier is complete and before submission, so the receipt does not expire during review.
  • Where a power needs correction at a cost of C$364.74, file within five working days of the withdrawal of approval to avoid it (RA 0001/2026, Anexo I, Article 24).

5. Verification checklist

  • □ All amounts are taken from the RM 347-2023 publication in force, with no historical figures used
  • □ The budget is split across the five nodes: registration, renewal, first-marketing testing, classification certificate and CLV
  • □ The payment date is logged and a six-month expiry reminder set
  • □ ROC validity is monitored during corrections to avoid cancellation and a second payment
  • □ Payment is scheduled after the dossier is complete and before submission
  • □ Any power correction was filed within five working days, avoiding the C$364.74 fee

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail